DIAGNOS Preserves Cash with C$125K Debt-for-Equity at C$0.20 to Fuel AI Eye Diagnostics

For healthcare organizations and clinicians evaluating AI diagnostic tools, the financial stability of the vendor is a critical due diligence factor. DIAGNOS’s decision to settle debt with shares instead of cash signals a lean operational posture that could allow it to continue refining its eye screening algorithms and pursuing regulatory clearances, but it also raises questions about its runway to reach widespread clinical adoption.

Diagnos Inc., a publicly traded Canadian AI-driven eye health diagnostics company, has announced a plan to settle two arm’s-length demand loans totaling C$125,000 by issuing 625,000 common shares at an issue price of C$0.20 per share. The agreements were signed on June 18, 2026, and the settlement is expected on June 25, 2026, with accrued interest through that date to be paid in cash. The transaction is designed to preserve cash on the company’s balance sheet, a move that highlights the financial realities facing early-stage healthcare technology firms. While the nominal amount is modest, the structure of the settlement—converting debt into equity at a fixed price—carries significant implications for existing shareholders and signals the company’s near-term liquidity constraints.

“

Diagnos Inc., a publicly traded Canadian AI-driven eye health diagnostics company, has announced a plan to settle two arm’s-length demand loans totaling C$125,000 by issuing 625,000 common shares at an issue price of C$0.20 per share.

For a company like DIAGNOS, which is still scaling its AI diagnostic platform for retinal and other eye-related conditions, cash is the lifeblood that funds clinical validation, regulatory submissions, and commercialization efforts. The fact that lenders agreed to accept shares suggests a belief in the long-term value proposition of the technology, but also likely indicates that DIAGNOS did not have sufficient cash on hand to comfortably retire the loans without threatening its operating runway. The issue price of C$0.20 per share provides an important reference point: it may be at, above, or below the prevailing market price. On the TSX Venture Exchange, where DIAGNOS trades under the symbol ADK, the stock has been thinly traded, and a forced equity raise of this nature can sometimes put downward pressure on the share price due to fear of dilution or signaling of financial distress.

The 625,000 new shares will be subject to a mandatory four-month-and-one-day hold period from the date of issuance, meaning they cannot be sold until late October 2026. This restricted period provides some immediate protection against a sudden flood of shares on the market, but once the hold expires, selling pressure could emerge if the lenders decide to liquidate. The true dilution impact, however, can only be gauged by comparing the new share count to the total outstanding shares—a figure not disclosed in the announcement. For a micro-cap company, even a seemingly small issue can represent a material percentage. The press release frames the move as a cash preservation strategy, but it is fundamentally a deleveraging and recapitalization event that shifts the company’s capital structure slightly more toward equity.